<DOC>
	<DOCNO>NCT00764660</DOCNO>
	<brief_summary>The purpose study assess effect SCH 900435 ( Org 25935 , MK-8435 ) heavy drinking , safety tolerability SCH 900435 participant alcohol dependence .</brief_summary>
	<brief_title>Trial Investigating Efficacy Safety SCH 900435 ( Org 25935 ) Relapse Prevention Participants With Alcohol Dependence ( P05718 )</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<criteria>Provide write informed consent scope nature investigation , explain participant screening ; Diagnosis alcohol dependence meeting least 5 7 criterion accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) specifier ; one criterion 1 ( tolerance ) 2 ( withdrawal ) ; Primary complaint accord MiniInternational Neuropsychiatric Interview ( MINI ) alcohol problem ; Participants must go detoxification program , clearly state desire stay abstinent present baseline following : alcohol abstinent least 3 day , benzodiazepine free least 3 day , Clinical Institute Withdrawal Assessment ( CIWA ) score &lt; 10 ; Age 1865 year screen ; Males , females childbearing potential ( i.e. , surgically sterile , postmenopausal least one year ) nonpregnant , nonlactating use medically accept method contraception ; include condom without spermicidal agent , diaphragm cervical cap spermicide , medically prescribe intrauterine device ( IUD ) , hormonal contraceptive ; Body Mass Index ( BMI ) &gt; 16 kg/m^2 ; Breath alcohol concentration &lt; 0.02 % ( screen baseline ) Participants require pharmacological treatment primary diagnosis major depressive disorder , anxiety , panic disorder social phobia ; Participants psychotic disorder ( accord MINI ) ; Participants medium high suicidality risk ( assessed MINI ) Active substance abuse ( result either physical mental damage define International Statistical Classification Diseases Related Health Problems , 10th revision [ ICD10 ] dependence alcohol ( exclude nicotine ) within 12 month prior screen , e.g . cannabis , benzodiazepine , amphetamine , chlo ( r ) methiazole , opiates , cocaine , hallucinogens substance ; Use one follow drug last 14 day prior screen : cannabis , amphetamine , opiate , cocaine , hallucinogen ; Use medication effect alcohol consumption within 30 day study initiation , include naltrexone , acamprosate , disulfiram , ondansetron , topiramate , selective serotonin reuptake inhibitor ( SSRIs ) , mirtazapine , varencicline , gabapentin , levetiracetam ; A clinically relevant visual disturbance , cataract , color blindness , macular degeneration , glaucoma retinal disease ; Untreated uncompensated clinically significant renal , endocrine , hepatic , respiratory , cardiovascular , hematological , immunological cerebrovascular disease , malignancy , chronic and/or degenerative process screening ; Any clinically meaningful abnormal laboratory , vital sign , physical examination electrocardiogram ( ECG ) finding , opinion investigator , may interfere interpretation safety efficacy evaluation ; QTc interval ( Fridericia correct ) screen &gt; 450 m ( male ) , &gt; 470 m ( female ) ; Serious neuropsychiatric condition impair judgment cognitive function ( include dementia amnestic disorder ) extent provide informed consent comply treatment preclude ; History present evidence epileptic disorder withdrawal seizure ; History substance withdrawal delirium ; Breastfeeding woman , positive result urine pregnancy test ( screen ) , plan become pregnant course trial ( female ) ; Pending legal charge potential incarceration , probation , parole ; Homelessness ( less 2 month stable residence ) ; Participation clinical trial 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>